Familial Hypercholesterolemia Explained: The Genetic Side of High Cholesterol

You eat well, exercise regularly, and maintain a healthy weight - yet your LDL cholesterol remains stubbornly, dangerously high. Your doctor prescribes a statin. It helps, but your numbers still exceed safe targets. Sound familiar? If so, you may be among the estimated 25 to 35 million people worldwide living with familial hypercholesterolemia - the most common serious genetic disorder most people have never heard of.

Familial hypercholesterolemia (FH) is the most common autosomal-dominant genetic disorder affecting lipid metabolism, characterized by lifelong, severely elevated LDL cholesterol from birth - not because of poor diet or sedentary habits, but because of a fundamental fault in how the body processes and clears cholesterol from the bloodstream. Despite affecting approximately 1 in 310 people globally, over 90% of FH cases remain undiagnosed. Most people with this condition do not know they have it until they have a heart attack.

That is the crisis at the heart of familial hypercholesterolemia: a common, treatable, and often preventable cause of early heart disease that medicine is still systematically failing to identify and treat. This article explains what FH is, how it works genetically, who is at risk, how it is diagnosed, what treatments exist - including a new generation of gene-silencing therapies - and what role natural metabolic support can play alongside medical treatment.

What Is Familial Hypercholesterolemia?

The Biology of Blocked Clearance

To understand FH, you need to understand how the body normally handles LDL cholesterol. Under healthy conditions, LDL particles circulating in the bloodstream are captured by LDL receptors on the surface of liver cells (hepatocytes), pulled inside, and broken down. This process continuously clears LDL from circulation, keeping blood levels within a safe range.

In FH, this clearance mechanism is impaired. The primary pathogenic mechanism of FH is dysfunction in LDL receptor-mediated catabolism of LDL. Because LDL receptors cannot efficiently capture and internalize LDL particles, cholesterol accumulates in the bloodstream from the earliest days of life. It accumulates not temporarily - as it might after a high-fat meal - but permanently and relentlessly, building up in arterial walls, forming plaques, narrowing vessels, and dramatically accelerating atherosclerosis.

Unlike diet-induced high cholesterol, which typically develops in adulthood and responds to lifestyle modification, FH is present from birth. A child born with heterozygous FH will have LDL cholesterol two to three times the normal range throughout their entire life - and without treatment, that lifelong cholesterol burden translates directly into premature cardiovascular disease. Without early detection and treatment, men with FH are likely to experience heart attacks between the ages of 40 and 50, and 85% of men with FH will have had a cardiac event by age 60.

The Three Forms: Heterozygous, Homozygous, and Compound Heterozygous

FH exists on a spectrum of severity determined by whether a person has inherited one or two defective copies of the causative gene:

Heterozygous FH (HeFH) - the most common form, occurring in approximately 1 in 250 individuals. A person inherits one mutated gene copy from one parent and one normal copy from the other. LDL cholesterol is typically 2 to 3 times normal - often in the range of 190 to 400 mg/dL untreated. HeFH significantly elevates cardiovascular risk but, with treatment initiated early enough, can be managed effectively.

Homozygous FH (HoFH) - the most severe form, occurring in approximately 1 in 250,000 to 300,000 individuals. Both copies of the relevant gene are defective - inherited from two carrier parents. LDL cholesterol levels are extreme, often 6 to 10 times normal, ranging from 400 to 1,000 mg/dL. Survival beyond age 30 is difficult without aggressive treatment - cardiovascular events frequently occur in childhood or adolescence.

Compound Heterozygous FH - a person has two different mutations in the same gene, one from each parent. Clinical severity typically falls between HeFH and HoFH.

The distinction matters enormously for treatment planning: HeFH may respond adequately to statins and ezetimibe, while HoFH almost always requires more powerful or invasive interventions including PCSK9 inhibitors, RNA-targeting therapies, or lipoprotein apheresis.

The Genetics of Familial Hypercholesterolemia

The Causative Genes

FH is caused by mutations in three primary genes:

LDLR (LDL Receptor gene) - mutations in this gene account for more than 90% of FH cases. Over 3,000 different pathogenic LDLR variants have been identified. The LDLR protein is the cellular machinery that captures LDL from circulation - mutations impair this protein's function, quantity, or ability to recycle, reducing or eliminating LDL clearance from the blood.

APOB (Apolipoprotein B gene) - mutations here account for approximately 5% of cases. ApoB is the protein on the surface of LDL particles that binds to LDL receptors. When ApoB is mutated, LDL particles cannot "dock" properly with receptors even when those receptors are functioning normally - the result is the same: impaired LDL clearance.

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9 gene) - gain-of-function mutations in PCSK9 account for less than 2% of FH cases. PCSK9 is a protein that marks LDL receptors for degradation - normally, it prevents receptor recycling to fine-tune cholesterol regulation. Gain-of-function mutations cause PCSK9 to destroy LDL receptors at an accelerated rate, dramatically reducing the number of functional receptors available and causing LDL to accumulate. The PCSK9 gene, paradoxically, became the target of some of the most powerful FH treatments developed in the past decade.

A meta-analysis published in JACC analyzing 11 million subjects worldwide confirmed that elevated lipoprotein(a) - Lp(a), another largely genetically determined lipid - may explain an additional 25% of clinical FH diagnoses, adding a fourth genetic layer to the condition's complexity.

Autosomal Dominant Inheritance: Why FH Runs in Families

FH is inherited in an autosomal dominant pattern - meaning one defective copy of the causative gene is sufficient to cause the disorder. Every child of an affected parent has a 50% chance of inheriting the mutation. This is why cascade screening - testing the first-degree relatives (parents, siblings, and children) of every identified FH patient - is recognized internationally as the most effective and cost-efficient strategy for finding new cases.

Each confirmed FH diagnosis is, in effect, a signal that several family members may also be affected - and many of those family members are currently undiagnosed.

Why Genetic Testing Matters

A 2025 study published in PMC examining cardiovascular patients in Eastern European populations found that only 10.5% of carriers of pathogenic or likely pathogenic LDLR and APOB variants had a prior diagnosis of FH. Among those with the highest-risk mutations, cardiovascular disease was present in 60% - yet the vast majority had never received a genetic diagnosis or appropriate treatment. This diagnostic failure is not unique to Eastern Europe. It is a global pattern.

Genetic testing for LDLR, APOB, and PCSK9 variants provides definitive confirmation of FH, guides treatment intensity, enables cascade family screening, and removes any ambiguity about whether elevated LDL reflects genetics or lifestyle. Increasingly, both clinical genetics and cardiology guidelines recommend genetic testing as an integral part of FH diagnosis and management.

Recognizing Familial Hypercholesterolemia: Signs, Symptoms, and Red Flags

The Silent Killer Problem

FH is most dangerous because it rarely announces itself through obvious symptoms until significant arterial damage has already occurred. Most people with HeFH have no external signs of the condition at all. The disease progresses silently through childhood and young adulthood, steadily building cholesterol deposits in arterial walls and narrowing coronary vessels, until a cardiac event occurs. This is why awareness of family history and proactive lipid screening are critical.

Physical Signs: When Cholesterol Becomes Visible

In some cases - more commonly in more severe or long-undiagnosed FH - cholesterol deposits become visible externally:

Xanthomas - waxy, yellowish cholesterol deposits that form in tendons (particularly the Achilles tendon and the tendons on the back of the hands and feet) or in the skin. Tendon xanthomas are considered a hallmark of FH and, when present, strongly indicate the diagnosis. Recurrent Achilles tendonitis or unexplained arthritic complaints may be an early presentation.

Xanthelasmas - yellowish plaques around the eyelids, formed by cholesterol deposits beneath the skin. These are less specific to FH than tendon xanthomas but remain a relevant clinical finding.

Corneal arcus - a grey-white ring around the cornea of the eye, caused by cholesterol deposition in the corneal stroma. When this finding appears in a person under 45 years of age, it is strongly associated with FH and warrants immediate lipid testing.

Family History: The Most Important Clinical Signal

Careful family history is essential for FH assessment. Key red flags that should trigger lipid testing and consideration of FH include:

• A first-degree relative with premature coronary artery disease (before age 55 in men, before age 60 in women)
• A family member known to have very high LDL cholesterol
• A family member who died suddenly of an unexplained cardiac event at a young age
• A parent or sibling known to have FH

These signals are powerful diagnostic cues. FH is, by definition, a familial condition - and the most efficient way to find it is through the families of those already diagnosed.

How Familial Hypercholesterolemia Is Diagnosed

Lipid Panel Thresholds

Diagnosis begins with a fasting lipid panel. The diagnostic LDL thresholds for FH consideration in adults are:

• LDL-C above 190 mg/dL in adults is a widely used clinical threshold that triggers FH evaluation, particularly when combined with family history
• In children, an LDL-C persistently above 160 mg/dL (or above 130 mg/dL with a positive family history) warrants investigation

Universal lipid screening in children - ideally between ages 9 and 11 and again between 17 and 21 - is advocated by pediatric cardiovascular specialists as the most effective strategy for catching FH early, when cholesterol-lowering treatment is most beneficial and when the disease trajectory can be most dramatically altered.

Clinical Scoring Systems

Several validated clinical scoring tools are used globally to diagnose FH without genetic testing:

Dutch Lipid Clinic Network (DLCN) Score - the most widely used international diagnostic tool, assigning points for LDL level, family history, personal cardiovascular history, physical findings (xanthomas, corneal arcus), and genetic test results. Scores of 6 to 8 indicate probable FH; scores of 9 or above indicate definite FH.

Simon Broome Register Criteria - a UK-based diagnostic framework incorporating total cholesterol and LDL thresholds alongside family history and physical findings.

MEDPED (Make Early Diagnosis, Prevent Early Deaths) - a US-developed tool using LDL thresholds adjusted for age and family history.

These scoring systems are practical clinical tools, but genetic confirmation provides the most definitive and actionable diagnosis.

When Genetic Testing Is Indicated

Genetic testing should be considered when: clinical scoring suggests probable or definite FH; LDL remains severely elevated despite treatment; homozygous FH is suspected; a family member has a confirmed FH mutation; or when the distinction between HoFH and severe HeFH would alter treatment decisions. A 2023 update from the European Atherosclerosis Society formalized genetic analysis as a core component of homozygous FH evaluation.

The Cardiovascular Risk: Why Early Treatment Is Life-Saving

Individuals with FH have a 20-fold increased risk of premature atherosclerotic cardiovascular disease compared to the general population. But this statistic contains a powerful corollary: with early diagnosis and treatment initiated in childhood or young adulthood, the risk of coronary heart disease can be reduced to rates comparable to the general population.

The reason this is possible is cumulative cholesterol exposure. The damage from FH is dose-dependent over time - decades of elevated LDL accumulate as arterial plaque. Every year of uncontrolled LDL adds to that burden. Conversely, every year of effective LDL lowering, begun early, reduces it. The cardiovascular system can absorb and compensate for moderate LDL elevation when it is brought under control early; it cannot recover from 40 years of untreated LDL at 300 mg/dL.

A cross-sectional study published in PMC examining FH prevalence and cardiovascular outcomes found that probable FH was independently associated with an adjusted odds ratio of 40.6 for prevalent cardiovascular disease - compared to just 8.15 for possible FH. The clinical gradient is stark: the more severe and untreated the FH, the more devastating the cardiovascular consequences.

Treatment Options: From Statins to Gene Silencing

Statins: The Cornerstone of FH Management

High-intensity statin therapy remains the first-line, gold-standard treatment for FH in both adults and children. Statins work by inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By reducing cholesterol production, statins trigger upregulation of LDL receptors on liver cells - increasing LDL clearance from circulation.

Pediatric FH treatment studies have demonstrated 20 years of safety data for statin therapy in children, with both atorvastatin and pitavastatin demonstrating efficacy and tolerability. Most FH patients require statins throughout their lives, and nearly 100% of people with FH will need cholesterol-lowering medication - lifestyle modification alone is insufficient because the disorder is genetic, not behavioral. Most patients with FH need to reduce their LDL by at least 50% to reach guideline-recommended targets, according to the European Society of Cardiology.

Ezetimibe: Complementary Intestinal Cholesterol Blockade

Ezetimibe reduces cholesterol absorption in the small intestine, working through a mechanism completely different from statins. It is typically added to statin therapy when LDL targets are not met on statins alone - a common scenario in FH. The combination of a high-intensity statin with ezetimibe can produce LDL reductions of 50 to 60% in HeFH patients.

PCSK9 Inhibitors: The Game-Changing Biologics

The discovery of PCSK9's role in LDL receptor degradation led directly to one of the most important therapeutic advances in cardiovascular medicine in decades. PCSK9 inhibitor monoclonal antibodies - including evolocumab (Repatha) and alirocumab (Praluent) - work by binding to circulating PCSK9 protein, preventing it from marking LDL receptors for destruction and thereby dramatically increasing the number of functional receptors available to clear LDL.

PCSK9 inhibitors lower LDL-C by 50 to 60% and reduce cardiovascular events proportionally to the LDL reduction achieved. A meta-analysis of 23 randomized controlled trials involving 4,282 FH patients found that PCSK9-targeting therapies reduced LDL-C by a pooled mean of 46.64% compared to control. They are typically administered as subcutaneous injections every 2 to 4 weeks and are indicated for FH patients who cannot reach LDL targets with statins and ezetimibe, or who are statin-intolerant.

Inclisiran: Twice-Yearly Gene Silencing

Inclisiran represents the next generation of PCSK9-targeted therapy - not an antibody that blocks the protein, but a small interfering RNA (siRNA) that silences the PCSK9 gene itself. Delivered via injection just twice per year, inclisiran works inside liver cells, degrading PCSK9 messenger RNA before it can be translated into the PCSK9 protein, thereby preventing LDL receptor degradation at the molecular level upstream.

The ORION-9 phase 3 trial confirmed inclisiran's efficacy for HeFH - and the ORION-5 trial confirmed benefit in HoFH patients as well. The V-DIFFERENCE trial results presented at the ESC 2025 Congress further highlighted inclisiran's efficacy in combination with lipid-lowering therapy, with no muscle-related adverse events. Its twice-yearly dosing is a major adherence advantage over the every-2-to-4-week administration required by monoclonal antibody PCSK9 inhibitors.

Bempedoic Acid: A Non-Statin Cholesterol Synthesis Inhibitor

Bempedoic acid inhibits ATP-citrate lyase (ACLY), an enzyme in the cholesterol synthesis pathway that operates upstream of the target of statins. Because it is only activated in liver tissue - not muscle tissue - bempedoic acid avoids the myopathy (muscle pain) that leads some patients to discontinue statins. It is particularly useful for statin-intolerant patients with FH who need additional LDL lowering.

Lipoprotein Apheresis: Mechanical LDL Removal

For homozygous FH and severe heterozygous FH where LDL cannot be adequately controlled through medication, lipoprotein apheresis offers a non-pharmacological intervention. Similar in principle to dialysis, the procedure removes LDL particles directly from blood plasma extracorporeally - passing the patient's blood through a device that selectively binds and removes LDL. It is typically performed every 1 to 2 weeks and can reduce LDL by 50 to 75% per session, though LDL levels rebound between treatments.

Emerging Gene Therapies: CRISPR and AAV-Mediated Approaches

The most exciting frontier in FH treatment is gene therapy - the prospect of a one-time or infrequent treatment that permanently corrects the underlying genetic defect rather than managing its consequences indefinitely.

VERVE-101 is a CRISPR base-editing therapy designed to permanently inactivate the PCSK9 gene in hepatocytes - eliminating PCSK9 production and maximally upregulating LDL receptors for life. Phase 1 trial results in humans with HeFH have been reported, demonstrating dose-dependent LDL reductions.

AAV-mediated gene therapy approaches aim to deliver functional copies of the LDLR gene directly into liver cells, restoring the lost cholesterol-clearing capacity in LDLR-deficient HoFH patients.

Anti-ANGPTL3 antibody therapy - a January 2026 journal scan published by the ACC confirmed that anti-ANGPTL3 antibody treatment is effective and safe for targeting LDL-C in HoFH - adding another mechanism to the growing toolkit for the most severe patients.

A CORALreef AddOn study reported at the ACC in March 2026 demonstrated that a novel PCSK9 inhibitor further reduced LDL-C in patients not meeting goals on existing therapy, continuing the rapid expansion of treatment options.

These gene therapy approaches are not yet widely available but represent the likely future of FH management: a shift from lifelong medication to curative or near-curative single interventions.

The Underdiagnosis Crisis: Why 90% of FH Is Still Missed

Despite decades of established clinical criteria, effective treatments, and clear evidence that early diagnosis prevents premature death, over 90% of FH cases remain undiagnosed worldwide. The reasons are systemic and interconnected:

Lack of universal childhood screening - most countries do not mandate lipid testing in children, meaning FH often goes undetected until adulthood or a cardiac event. Advocates for universal lipid screening (ULS) in pediatric populations argue persuasively that early detection in children is the single highest-impact intervention available.

Attributing high LDL to diet and lifestyle - clinicians and patients alike often assume that high cholesterol reflects poor lifestyle choices, delaying investigation of genetic causes in patients who maintain healthy habits but still have persistently elevated LDL.

Incomplete cascade screening - when one family member is diagnosed with FH, their relatives should be automatically offered testing. This cascade screening approach is effective and cost-efficient, but implementation remains inconsistent globally.

Low clinical awareness - FH is not always included in medical education curricula with the prominence it deserves, and primary care clinicians may not recognize the pattern of persistently elevated LDL that warrants FH investigation.

The consequences of this underdiagnosis are measured in preventable heart attacks and premature deaths across multiple generations of affected families.

Natural Support Alongside Medical Management: The Role of Berberine and Hydroxytyrosol

Where Natural Medicine Fits in FH

A critical clarification upfront: FH is a genetic disorder requiring medical treatment. Lifestyle modification and natural supplements cannot correct the underlying LDL receptor dysfunction, APOB mutation, or PCSK9 gain-of-function that characterizes FH. Nearly 100% of people with FH will need cholesterol-lowering medications, and this is non-negotiable for cardiovascular safety.

However, natural compounds with documented mechanisms of action on LDL metabolism and oxidative stress can provide meaningful complementary support within a medically supervised management plan - potentially helping patients reach LDL targets, protect arterial health, and address the inflammatory dimension of atherosclerosis that standard lipid panels do not fully capture.

Berberine: A Nature-Derived PCSK9 Suppressor

Berberine has attracted serious clinical attention for its mechanism of action on LDL clearance. Research has established that berberine acts through at least two complementary pathways: upregulating LDL receptor expression by stabilizing LDLR mRNA in hepatocytes, and suppressing PCSK9 expression by accelerating degradation of hepatocyte nuclear factor 1α (HNF1α), thereby reducing PCSK9's destruction of LDL receptors.

This dual mechanism - directly mirroring the biological pathways that PCSK9 inhibitor drugs target - has led researchers to describe berberine as a "nature-made PCSK9 inhibitor." A systematic review and meta-analysis of 27 randomized controlled trials found that berberine reduced LDL-C by a pooled mean of 0.65 mmol/L, triglycerides by 0.39 mmol/L, total cholesterol by 0.66 mmol/L, and increased HDL-C by 0.07 mmol/L, with no serious adverse events reported. A separate clinical review found berberine alone or in combination provided an average LDL percent reduction of 20 to 30% - comparable, though not equivalent, to moderate-intensity statin therapy.

Naturem™ Glucose Guard combines berberine-containing Coptis teeta with hydroxytyrosol, Gymnema sylvestre, and chromium in a multi-pathway formula that simultaneously supports blood sugar regulation and lipid balance. As documented on the Naturem™ barberry ingredient page, the formula promotes heart health by lowering LDL and triglycerides while supporting HDL - making it relevant as a complementary metabolic support tool for individuals managing cholesterol through an integrated approach.

Berberine's mechanism is different from - and potentially synergistic with - both statins and PCSK9 inhibitors. Statins reduce cholesterol synthesis; PCSK9 inhibitors preserve LDL receptors from degradation; berberine increases LDLR expression while also suppressing PCSK9. For FH patients not reaching target LDL despite standard medications, discussing berberine as a complementary support tool with a physician is a reasonable clinical conversation.

Hydroxytyrosol: Protecting LDL From the Damage That Drives Atherosclerosis

For FH patients, the immediate problem is elevated LDL concentration. But the downstream danger is oxidized LDL - LDL particles that have been damaged by free radicals and become far more likely to penetrate arterial walls, trigger macrophage activation, and initiate the inflammatory cascade that builds atherosclerotic plaque. Studies show that hydroxytyrosol - the primary polyphenol in olive oil - efficiently protects LDL particles from oxidative damage, limiting lipid peroxidation through radical scavenging and antioxidant enzyme stimulation.

The European Food Safety Authority has formally recognized that olive oil polyphenols including hydroxytyrosol contribute to the protection of blood lipids from oxidative stress - a designation grounded in the evidence base reviewed in a comprehensive 2020 PMC systematic review of hydroxytyrosol's cardiovascular mechanisms. A randomized double-blind, placebo-controlled 12-week clinical study demonstrated a significant reduction in LDL-C in the hydroxytyrosol group compared to placebo. Combined with berberine and red yeast rice in another clinical study, hydroxytyrosol formulations produced a 24% reduction in LDL-C and 20% reduction in oxidized LDL.

For someone managing FH - in whom LDL is structurally elevated and arterial wall protection is a lifetime priority - daily hydroxytyrosol intake through extra virgin olive oil or targeted supplementation provides meaningful protection against the oxidative damage that translates elevated LDL into arterial disease. Find out more about the cardiovascular mechanisms of hydroxytyrosol in this detailed clinical overview from SVK Herbal on hydroxytyrosol and heart health.

The Foundation: Diet, Exercise, and Lifestyle

While lifestyle change cannot cure FH, it can meaningfully reduce the overall cardiovascular risk burden in someone who already carries a genetic predisposition. For FH patients, key lifestyle priorities include:

• A Mediterranean-style diet rich in olive oil, fish, legumes, and vegetables - consistently associated with reduced LDL oxidation and cardiovascular events
• Regular aerobic exercise - which raises HDL, reduces triglycerides, and improves LDL particle size as detailed in the clinical evidence reviewed in our companion article on exercise and cholesterol
• Smoking cessation - smoking dramatically accelerates arterial damage in someone already at high LDL burden
• Alcohol minimization - excess alcohol elevates triglycerides and worsens the overall lipid profile
• Weight management - visceral adiposity compounds the insulin resistance that worsens dyslipidemia

What to Do If You Think You or Your Child Has FH

The path from suspicion to diagnosis and treatment is straightforward:

• Request a fasting lipid panel. If LDL-C is above 190 mg/dL in an adult, or above 160 mg/dL in a child, ask your doctor specifically about familial hypercholesterolemia.
• Review your family history. Ask your parents, siblings, and relatives about their cholesterol levels and whether any family member had a heart attack, stroke, or cardiac death before age 60. This family history is the single most important piece of the diagnostic puzzle.
• Request a Dutch Lipid Clinic Network score assessment or referral to a lipid specialist or clinical geneticist with experience in FH.
• Ask about genetic testing. Genetic confirmation of an LDLR, APOB, or PCSK9 mutation enables cascade screening of family members - potentially identifying multiple relatives who also need treatment.
• If FH is confirmed, ensure all first-degree relatives are tested. Each identified FH patient has a 50% probability of having passed the mutation to their children and a 50% probability of sharing it with each parent and sibling.
• Begin treatment early. The greatest cardiovascular protection from FH treatment comes from starting lipid-lowering therapy before arterial damage accumulates - ideally in childhood for confirmed HeFH.

Conclusion: The Genetic Cholesterol That Medicine Must Not Keep Missing

Familial hypercholesterolemia is not a rare, exotic condition. It is the most common serious genetic disorder affecting lipid metabolism - present in 1 in 250 people worldwide, in every ethnic group, on every continent. It is responsible for a substantial proportion of premature heart attacks in young adults who should have had decades more of healthy life.

The treatment pathway exists. PCSK9 inhibitors, inclisiran, statins, ezetimibe, and the emerging gene therapies now in clinical development represent a therapeutic arsenal that, when applied early enough, can reduce FH-driven cardiovascular risk to levels comparable to the general population. But none of these treatments can be applied to patients who have not yet been diagnosed.

The imperative is clear: universal childhood lipid screening, cascade family testing after every FH diagnosis, greater clinical awareness of the genetic dimension of persistently elevated LDL, and the integration of natural complementary support - including the LDL-protective effects of hydroxytyrosol and the PCSK9-modulating properties of berberine - alongside medical management. Together, these tools represent the complete picture of what is now possible for FH patients.

If you have a family history of early heart disease or have been told your LDL is persistently high despite a healthy lifestyle, ask for an FH evaluation. It may be the most important medical question you ever ask.

This article is for informational purposes only and does not constitute medical advice. Familial hypercholesterolemia is a serious medical condition requiring professional diagnosis and treatment. Always consult a qualified healthcare provider before making changes to your medication, supplement regimen, or management plan.